These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
455 related articles for article (PubMed ID: 34721412)
1. Molecular Changes in the Adipose Tissue Induced by Rheumatoid Arthritis: Effects of Disease-Modifying Anti-Rheumatic Drugs. Arias de la Rosa I; Escudero-Contreras A; Ruiz-Ponce M; Román-Rodríguez C; Pérez-Sánchez C; Ábalos-Aguilera MDC; Ortega-Castro R; Alcaide J; Murri M; Font P; Calvo-Gutiérrez J; Luque-Tevar M; Patiño-Trives AM; Guzmán-Ruiz R; Malagón MDM; Tinahones FJ; Collantes-Estévez E; López-Pedrera C; Barbarroja N Front Immunol; 2021; 12():744022. PubMed ID: 34721412 [TBL] [Abstract][Full Text] [Related]
2. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. Moreland LW; O'Dell JR; Paulus HE; Curtis JR; Bathon JM; St Clair EW; Bridges SL; Zhang J; McVie T; Howard G; van der Heijde D; Cofield SS; Arthritis Rheum; 2012 Sep; 64(9):2824-35. PubMed ID: 22508468 [TBL] [Abstract][Full Text] [Related]
3. Longitudinal monitor of Jun N-terminal kinase pathway associated phosphatase reflects clinical efficacy to triple conventional disease-modifying anti-rheumatic drugs treatment in rheumatoid arthritis patients. Song D; Zhu X; Wang F; Sun J Inflammopharmacology; 2021 Aug; 29(4):1131-1138. PubMed ID: 34254203 [TBL] [Abstract][Full Text] [Related]
4. Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort. Lukas C; Mary J; Debandt M; Daïen C; Morel J; Cantagrel A; Fautrel B; Combe B Arthritis Res Ther; 2019 Nov; 21(1):243. PubMed ID: 31730497 [TBL] [Abstract][Full Text] [Related]
5. Defective glucose and lipid metabolism in rheumatoid arthritis is determined by chronic inflammation in metabolic tissues. Arias de la Rosa I; Escudero-Contreras A; Rodríguez-Cuenca S; Ruiz-Ponce M; Jiménez-Gómez Y; Ruiz-Limón P; Pérez-Sánchez C; Ábalos-Aguilera MC; Cecchi I; Ortega R; Calvo J; Guzmán-Ruiz R; Malagón MM; Collantes-Estevez E; Vidal-Puig A; López-Pedrera C; Barbarroja N J Intern Med; 2018 Jul; 284(1):61-77. PubMed ID: 29532531 [TBL] [Abstract][Full Text] [Related]
6. Sinomenine Inhibits the Progression of Rheumatoid Arthritis by Regulating the Secretion of Inflammatory Cytokines and Monocyte/Macrophage Subsets. Liu W; Zhang Y; Zhu W; Ma C; Ruan J; Long H; Wang Y Front Immunol; 2018; 9():2228. PubMed ID: 30319663 [TBL] [Abstract][Full Text] [Related]
7. Clinical deep remission and related factors in a large cohort of patients with rheumatoid arthritis. Liu JJ; Li R; Gan YZ; Zhang RJ; Li J; Cai YM; Zhao JX; Liao H; Xu J; Shi LJ; Li J; Li SG; Sun XL; He J; Liu X; Ye H; Li ZG Chin Med J (Engl); 2019 May; 132(9):1009-1014. PubMed ID: 30946065 [TBL] [Abstract][Full Text] [Related]
8. Body mass index does not affect response of rituximab in patients with rheumatoid arthritis: results from the TURKBİO registry. Karataş A; Pişkin Sağir R; Koca SS; Dalkiliç E; Can G; Pehlivan Y; Yazici A; Inanç N; Cefle A; Ertürk Z; Akar S; Şenel S; Birlik M; Akkoç N; Önen F Turk J Med Sci; 2023; 53(5):1321-1329. PubMed ID: 38813042 [TBL] [Abstract][Full Text] [Related]
9. A population model of early rheumatoid arthritis disease activity during treatment with methotrexate, sulfasalazine and hydroxychloroquine. Wojciechowski J; Wiese MD; Proudman SM; Foster DJ; Upton RN Br J Clin Pharmacol; 2015 May; 79(5):777-88. PubMed ID: 25394211 [TBL] [Abstract][Full Text] [Related]
10. Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Uttley L; Bermejo I; Ren S; Martyn-St James M; Wong R; Scott DL; Young A; Stevenson M Pharmacoeconomics; 2018 Sep; 36(9):1063-1072. PubMed ID: 29546668 [TBL] [Abstract][Full Text] [Related]
11. Association between biologic disease modifying anti-rheumatic drugs and incident hypertension in patients with rheumatoid arthritis: Results from prospective nationwide KOBIO Registry. Kim SK; Kwak SG; Choe JY Medicine (Baltimore); 2020 Feb; 99(9):e19415. PubMed ID: 32118795 [TBL] [Abstract][Full Text] [Related]
12. Clinical Responses and Synovial Vascularity in Obese Rheumatoid Arthritis Patients Treated with Adalimumab and Methotrexate. Kaeley GS; MacCarter DK; Pangan AL; Wang X; Kalabic J; Ranganath VK J Rheumatol; 2018 Dec; 45(12):1628-1635. PubMed ID: 30173153 [TBL] [Abstract][Full Text] [Related]
13. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438 [TBL] [Abstract][Full Text] [Related]
14. Inflammatory cytokine levels, disease activity, and function of patients with rheumatoid arthritis treated with combined conventional disease-modifying antirheumatic drugs or biologics. Osiri M; Wongpiyabovorn J; Sattayasomboon Y; Thammacharoenrach N Clin Rheumatol; 2016 Jul; 35(7):1673-81. PubMed ID: 27188857 [TBL] [Abstract][Full Text] [Related]
15. Factors influencing spinal sagittal balance, bone mineral density, and Oswestry Disability Index outcome measures in patients with rheumatoid arthritis. Masamoto K; Otsuki B; Fujibayashi S; Shima K; Ito H; Furu M; Hashimoto M; Tanaka M; Lyman S; Yoshitomi H; Tanida S; Mimori T; Matsuda S Eur Spine J; 2018 Feb; 27(2):406-415. PubMed ID: 29185111 [TBL] [Abstract][Full Text] [Related]
16. Association of Body Mass Index Categories with Disease Activity and Radiographic Joint Damage in Rheumatoid Arthritis: A Systematic Review and Metaanalysis. Vidal C; Barnetche T; Morel J; Combe B; Daïen C J Rheumatol; 2015 Dec; 42(12):2261-9. PubMed ID: 26523023 [TBL] [Abstract][Full Text] [Related]
17. Impact of body weight on the achievement of minimal disease activity in patients with rheumatic diseases: a systematic review and meta-analysis. Lupoli R; Pizzicato P; Scalera A; Ambrosino P; Amato M; Peluso R; Di Minno MN Arthritis Res Ther; 2016 Dec; 18(1):297. PubMed ID: 27964760 [TBL] [Abstract][Full Text] [Related]
18. Predictors for low disease activity and remission in rheumatoid arthritis patients treated with biological DMARDs. Wacharapornin P; Suwannalai P J Med Assoc Thai; 2014 Nov; 97(11):1157-63. PubMed ID: 25675680 [TBL] [Abstract][Full Text] [Related]
19. Longitudinal associations between body mass index and changes in disease activity and radiographic progression in rheumatoid arthritis patients treated with infliximab. Burkard T; Vallejo-Yagüe E; Lauper K; Finckh A; Hügle T; Burden AM RMD Open; 2023 Oct; 9(4):. PubMed ID: 37802600 [TBL] [Abstract][Full Text] [Related]
20. Effects of disease modifying anti-rheumatic drugs on subclinical atherosclerosis and endothelial dysfunction which has been detected in early rheumatoid arthritis: 1-year follow-up study. Guin A; Chatterjee Adhikari M; Chakraborty S; Sinhamahapatra P; Ghosh A Semin Arthritis Rheum; 2013 Aug; 43(1):48-54. PubMed ID: 23415602 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]